Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sodium channel protein type 1, 2, and 3 subunit alpha are the core pore-forming subunits of voltage-gated sodium channels (Nav1.1, Nav1.2, Nav1.3), essential for the initiation and propagation of action potentials in neurons and muscle cells[1][2][6]. These channels are transmembrane proteins comprising four homologous domains, each containing six transmembrane segments; their S4 segments act as voltage sensors, conferring voltage-dependent gating[1][2]. The channels are critical for rapid depolarization of excitable cells, and mutations in the encoding genes (SCN1A, SCN2A, SCN3A) are linked to various neurological disorders, including epilepsy and developmental encephalopathies[4][6]. Voltage-gated sodium channels are major drug targets for anticonvulsants, local anesthetics, and antiarrhythmics, which act predominantly by blocking or stabilizing inactive conformations of these channels[2][4].
Blockade of sodium ion flux through channel pore; Stabilization of inactivated channel state; Inhibition of repetitive neuronal firing
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sodium channel protein type 1, 2, and 3 subunit alpha (Nav1.1 (SCN1A), Nav1.2 (SCN2A), Nav1.3 (SCN3A)).